Funding

No external funding was used in the preparation of this letter.

Conflict of interest

Dr. Anadkat has served as a consultant for ImClone, Bristol Myers Squibb, AstraZeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli Lilly, Abbvie, Boehringer-Ingelheim, Innovaderm, UCB Biopharma, Novocure, OnQuality, and Springworks. Dr. Anadkat has served as a Principal Investigator for Novartis, Boehringer-Ingelheim, Lutris, OnQuality, UCB Biopharma, InflamRx, Eli Lilly, InCyte, Abbvie, AnaptysBio, Hana Biosciences, Xoma, Veloce, Biogen, Xbiotech, and Chemocentryx. Dr. Choi has a consultant role with OnQuality, Regeneron, Parexel, Azitra, La Roche-Posay Pharmaceuticals, and PraHealthSciences. Dr. Choi has served as a consultant for Biotest AG, Keratin Biosciences, Bristol Meyers Squibb, Novartis, Array Biopharma, and Kyowa Kirin International. Dr. Choi has served as a Principal Investigator for OnQuality, InCyte, and Veloce. Dr. Jung has a consultant role at Regeneron and Sanofi. Dr. Lacouture has a consultant role with Oncoderm Labs, Johnson and Johnson, Novocure, QED, Bicara, Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, AstraZeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Azitra, Roche, Oncoderm, NCODA, and Apricity. Dr. Lacouture also receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis, National Institutes of Health, and AstraZeneca. Dr. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics. Dr. Markova has a consultant role with Alira Health and Blueprint Medicines, and receives research funding from Amryt Pharma and Incyte Corp. Dr. Noor has a consultant role with Kyowa Kirin. Dr. Sibaud has received consulting fees from Amgen, Bristol Myers Squibb, Pierre Fabre, and Bayer. Dr. Sibaud has received honoraria for lectures from Bristol Myers Squibb, Pierre Fabre, Novartis, and Incyte. Dr. Sibaud participates on a data safety monitoring board for Bristol Myers Squibb. Dr. Rossi has served as a consultant for Almirall, Mavig, Dynamed, Canfield Scientific, Allergan Inc., Biofrontera, MD, Lam Therapeutics, Regeneron, Cutera, Skinfix, and L’Oreal. Dr. Rossi has received research funding from Regen, LeoPharma, and Biofrontera. Dr. Rossi serves on the editorial boards for Lasers in Surgery and Medicine, Cutis, Journal of the American Academy of Dermatology, and Dermatologic Surgery. Alexander Bang and Dr. Gordon have no conflicts of interest that might be directly relevant to the contents of this letter.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable

Availability of data and material

Data of the supporting information are available upon request from the authors and a directory of oncodermatologists is available from oncodermatologysociety.org.

Code availability

Not applicable.

Authors’ contributions

Conception and design: ASB and MEL. Acquisition of data: ASB and MEL. Analysis and interpretation of data: ASB, MJB, JNN, NRL, JYJ, AM, AG, AMM, SJN, VS, and MEL. Critical revision of the manuscript: ASB, MJB, JNN, NRL, JYJ, AM, AG, AMM, SJN, VS, and MEL.